Morningstar
•
Nov 02, 2026
AstraZeneca PLC: AstraZeneca Earnings: Excellent Growth, Three-Year Restructuring Program To Invest in Pipeline
Summary
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Regeneron Pharmaceuticals, Inc.
Nov 02, 2026
•
REGN
Analyst Report: Sanofi
Nov 02, 2026
•
SNY
Analyst Report: AbbVie Inc.
Nov 02, 2026
•
ABBV
Analyst Report: Regeneron Pharmaceuticals, Inc.
Oct 30, 2026
•
REGN
Analyst Report: Gilead Sciences, Inc.
Oct 30, 2026
•
GILD
